Pregnancy outcome after TNF‐α inhibitor therapy during the first trimester: a prospective multicentre cohort study
British Journal of Clinical Pharmacology2015Vol. 80(4), pp. 727–739
Citations Over TimeTop 1% of 2015 papers
Corinna Weber‐Schoendorfer, Marc Oppermann, Evelin Wacker, Nathalie Bernard, Delphine Beghin, Benedikte Cuppers‐Maarschalkerweerd, Jonathan L. Richardson, Laura E. Rothuizen, Alessandra Pistelli, Heli Malm, Georgios Eleftheriou, Debra Kennedy, Mine Kadıoğlu, Reinhard Meister, Christof Schaefer
Abstract
TNF-α inhibitors may carry a risk of adverse pregnancy outcome of moderate clinical relevance. Considering the impact of insufficiently controlled autoimmune disease on the mother and the unborn child, TNF-α inhibitors may nevertheless be a treatment option in women with severe disease refractory to established immunomodulatory drugs.
Related Papers
- → Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis(2008)377 cited
- → Effectiveness of infliximab after adalimumab failure in Crohn's disease.(2012)32 cited
- Effectiveness of infliximab after adalimumab failure in Crohn＇s disease(2012)
- → Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease(2013)17 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited